BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, May 22, 2026
Home » Topics » Disease categories and therapies » Cancer

Cancer
Cancer RSS Feed RSS

Malignant B-cell lymphocytes seen in Burkitt lymphoma, stained with hematoxylin and eosin (H&E) stain.
Cancer

Schroedinger’s MALT1 inhibitor shows preclinical activity in B cell tumors

Dec. 15, 2023
Previous studies with mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors have demonstrated their potential as antitumor agents across several tumor models when administered alone or in combination with standard treatments.
Read More
Photomicrograph of diffuse large B-cell lymphoma
Cancer

QPCTL inhibitor SC-2882 tested for diffuse large B-cell lymphoma

Dec. 15, 2023
Researchers from Weill Cornell Medicine and Scenic Biotech BV presented promising preclinical data on SC-2882, a first-in-class specific glutaminyl-peptide cyclotransferase-like (QPCTL) inhibitor that induces secondary proteolytic degradation of the monocyte chemo attractants CCL2 and CCL7 and inactivation of the “don’t-eat-me” signal CD47, as a novel therapeutic for diffuse large B-cell lymphoma (DLBCL).
Read More
Cancer

Zhejiang Wenda Pharma Technology describes new HER2 and mutant inhibitors for cancer

Dec. 15, 2023
Zhejiang Wenda Pharma Technology Ltd. has identified HER2 (erbB2) and its (exon 20 insertion [Ex20Ins], (Ala775_Gly776insTyrValMetAla)) mutant inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Chinese researchers divulge dual LSD1 and HDAC inhibitors

Dec. 15, 2023
Researchers at Sichuan Huiyu Pharmaceutical Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have synthesized hydroxyamide derivatives acting as dual lysine-specific histone demethylase 1A (KDM1A, LSD1) and histone deacetylase (HDAC) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
Read More
Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow
Immuno-oncology

Human T cells armed with bispecific T cell engaging Abs fight myeloma

Dec. 15, 2023
In a recent publication in Scientific Reports, researchers at City of Hope and collaborators presented a novel CS1 bsAb, called CS1-dbBiTE, conjugating an intact anti-CS1 antibody (elotuzumab) and an anti-human OKT3 antibody at their respective hinge regions using Click chemistry.
Read More
Cancer

FGFR1 is target for metastatic breast cancer

Dec. 15, 2023
Some of the mechanisms behind metastatic breast cancer remain poorly understood.
Read More
Immuno-oncology

Carisma nominates CAR-M lead candidate in Moderna collaboration

Dec. 15, 2023
Carisma Therapeutics Inc. has announced the nomination of its first lead candidate under a collaboration with Moderna Inc.
Read More
Real fluorescence microscopic view of human neuroblastoma cells
Cancer

Less is more: ALK inhibitors increase exposed ALK expression

Dec. 15, 2023
By Coia Dulsat
Researchers at Boston Children's Hospital and Harvard Medical School have explored the possibility of using anaplastic lymphoma kinase (ALK) as a target for the application of ALK.CAR T cells to treat neuroblastoma, the most common and deadliest tumor of infancy.
Read More

Carthera adds €4.5M, boosts series B funds to €42M

Dec. 14, 2023
By Shani Alexander
Carthera SA received an additional €4.5 million (US$4.9 million) from investors to take its series B funding round to €42 million despite a tough fundraising environment for med-tech companies. Frédéric Sottilini, CEO of Carthera, told BioWorld that the strong investor interest was testament to their confidence in the company’s Sonocloud technology for brain disorder treatment.
Read More
Cancer

Hangzhou Unogen Biotech presents new PRMT5 inhibitors for lymphoma

Dec. 14, 2023
Hangzhou Unogen Biotech Ltd. has divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of lymphoma.
Read More
Previous 1 2 … 543 544 545 546 547 548 549 550 551 … 4124 4125 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Acid alpha-glucosidase molecular structure isolated on black

    ‘Detargeted’ targeted gene therapy improves activity in Pompe

    BioWorld
    A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 19, 2026
  • Microscopic view of the ebola virus

    WHO declares Ebola outbreak a public health emergency of international concern

    BioWorld
    The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
  • Nxera Pharma prepares and tests new GPR17 antagonists

    BioWorld Science
    Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing